The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies

Four ongoing US public health surveillance studies gather information relevant to the prevalence, impact, and treatment of headache and migraine: the National Health Interview Survey, the National Health and Nutrition Examination Survey, the National Ambulatory Care Survey, and the National Hospital Ambulatory Medical Care Survey. The American Migraine Prevalence and Prevention (AMPP) study is a privately funded study that provides comparative US population‐based estimates of the prevalence and burden of migraine and chronic migraine.

[1]  S. Tepper,et al.  Intranasal Zolmitriptan for the Treatment of Acute Migraine , 2013, Headache.

[2]  R. Lipton,et al.  Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study , 2012, Headache.

[3]  R. Lipton,et al.  Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study , 2012, Headache.

[4]  R. Lipton,et al.  Use of the Emergency Department for Severe Headache. A Population‐Based Study , 2009, Headache.

[5]  K. Merikangas,et al.  Physical and Mental Comorbidity of Headache in a Nationally Representative Sample of US Adults , 2008, Psychosomatic medicine.

[6]  C. Vila,et al.  Crossover, double‐blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy , 2007, European journal of neurology.

[7]  R. Lipton,et al.  Probable Migraine in the United States: Results Of The American Migraine Prevalence and Prevention (AMPP) Study , 2007, Cephalalgia : an international journal of headache.

[8]  R. Lipton,et al.  Migraine prevalence, disease burden, and the need for preventive therapy , 2007, Neurology.

[9]  E. Loder,et al.  Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study , 2006, Headache.

[10]  R. Lipton,et al.  The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF) , 2005, The Journal of Headache and Pain.

[11]  A. Dowson,et al.  Speed of Onset and Efficacy of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine , 2003, CNS drugs.

[12]  W F Stewart,et al.  Migraine Diagnosis and Treatment: Results From the American Migraine Study II , 2001, Headache.

[13]  R. Lipton,et al.  Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II , 2001, Headache.

[14]  R. Lipton,et al.  Medical Consultation for Migraine: Results From the American Migraine Study , 1998, Headache.

[15]  K. Holmes,et al.  Detection of Treponema pallidum in lesion exudate with a pathogen-specific monoclonal antibody , 1985, Journal of clinical microbiology.

[16]  K. Holmes,et al.  Characterization of monoclonal antibodies to Treponema pallidum. , 1985, Journal of Immunology.

[17]  R. Stephens,et al.  Monoclonal antibodies to Chlamydia trachomatis: antibody specificities and antigen characterization. , 1982, Journal of immunology.